SEER Seer

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.

About Seer

Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit .

Investor Contact:

Carrie Mendivil

Media Contact:

Patrick Schmidt





EN
23/04/2024

Underlying

SEERSeer

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seer

 PRESS RELEASE
Free
SEER SEER

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

Seer to Report First Quarter 2024 Financial Results on May 8, 2024 REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay ...

April 23, 2024 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and P...

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter...

February 29, 2024 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

Seer to Participate in the TD Cowen 44th Annual Health Care Conference REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat and Q&A session on Monday, March 4th at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. A live webcast of the session will be available on the Investor s...

February 21, 2024 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Pro...

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies Proteograph Product Suite enables scalable deep, unbiased proteomics by mass spectrometry and overcomes the limitations of affinity-based methods REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for prote...

February 6, 2024 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on ...

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website a...

February 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch